Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004193 · ClinicalTrials.gov registry record · Phase 2
ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00004193 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 25 participants.
The verdict
NCT00004193, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: ISIS 2503 may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have metastatic and/or locally recurrent colorectal cancer.
Interventions
- DRUG ISIS 2503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1999-01 |
| Est. Completion | 2000-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004193
The ClinicalTrials.gov registry entry for NCT00004193 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ISIS 2503 is the first listed.
NCT00004193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004193 about?
NCT00004193 is a clinical study titled "ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer". RATIONALE: ISIS 2503 may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have metastatic and/or locally recurrent colorectal cancer.
What is the current status of trial NCT00004193?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 1999-01. Estimated completion is 2000-11.
What interventions are being tested in trial NCT00004193?
The interventions under investigation include: ISIS 2503 (DRUG).
Who is sponsoring clinical trial NCT00004193?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.